Reported $4,586.8 $3,864.1 19% $13,443.9 $11,445.7 17%
Total Sales -
Pro forma $4,586.8 $4,054.7 13% $13,516.6 $11,986.3 13%
(1) These amounts represent the reported Cialis sales in Lilly's financial
statements and do not include Cialis sales from the joint-venture
countries prior to the ICOS acquisition on January 29, 2007. Total
worldwide Cialis sales for the third quarter of 2007 of $311.4 million
represent 27 percent growth over the third quarter of 2006. September
year-to-date 2007 worldwide Cialis sales were $870.3 million and
represented 24 percent growth over the first nine months of 2006.
Significant Events Over the Last Three Months
-- The company today announced that it will acquire the exclusive rights
to teplizumab, a humanized anti-CD3 monoclonal antibody, from
MacroGenics, Inc. In addition, the two companies have entered into a
global strategic alliance to develop and commercialize teplizumab, as
well as other potential next-generation molecules for use in the
treatment of autoimmune diseases. Teplizumab is currently being studied
in the PROTEGE trial, a global pivotal Phase II/III clinical trial for
individuals with recent-onset type 1 diabetes.
-- The company submitted a supplemental new drug application to the U.S.
Food and Drug Administration for Cymbalta for the management of
-- In September, the U.S. Food and Drug Administration approved Evista for
a new use to reduce the risk of invasive breast cancer in two
populations: postmenopausal women with osteoporosis and postmenopausal
women at high risk for invasive breast cancer.
-- The company submitted an application with the European Medicines Agency
for centralized review of Alimta, in combination with cisplatin
|SOURCE Eli Lilly and Company|
Copyright©2007 PR Newswire.
All rights reserved